SEC Form 4 · accession 0001493152-18-010235
Provention Bio, Inc. · PRVB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Cameron Gray
Director
Period of report
Jul 19, 2018
Accepted (ET)
Jul 19, 2018 · 5:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001695357
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F2,F1 | $4.00 | Jul 19, 2018 | A | 128,981 | A | — | Jul 19, 2028 | Common Stock, par value $0.0001 | 128,981 | 128,981 | D |
| Warrant (right to buy)F3 | $2.50 | Jul 19, 2018 | C | 144,824 | A | Apr 25, 2017 | Apr 25, 2024 | Common Stock, par value $0.0001 | 144,824 | 144,824 | D |
Explanation of responses
- F1The option vests in eight equal semi-annual installments commencing on January 19, 2018 and will become fully vested on July 19, 2022.
- F2The securities were granted pursuant to the Issuer's 2017 Equity Incentive Plan, effective as of the closing of the Issuer's initial public offering of common stock.
- F3As previously reported on reporting person's Form 3 filed on July 3, 2018, upon consummation of the initial public offering of Provention Bio, Inc. (the "Issuer"), which closed on July 19, 2018, each share of Series A Preferred Stock will automatically convert into one share of Common Stock, par value $0.0001 per share ("Common Stock") and the Warrant will automatically convert into a warrant to purchase Common Stock.